Rituximab in RA-ILD: Treatment Recommendation
Rituximab is an effective and conditionally recommended first-line treatment option for rheumatoid arthritis-associated interstitial lung disease (RA-ILD), with evidence supporting stabilization or improvement of pulmonary function and a favorable safety profile compared to cyclophosphamide. 1, 2
Evidence-Based Treatment Approach
First-Line Therapy Positioning
The 2024 ACR/CHEST guidelines conditionally recommend rituximab as a first-line treatment option for RA-ILD, alongside mycophenolate (which ranks highest in the treatment hierarchy), azathioprine, and cyclophosphamide 2. The 2025 Italian Society of Rheumatology systematic review and meta-analysis, encompassing 7,879 RA-ILD patients across 69 studies, confirms that rituximab is associated with stabilization or improvement of forced vital capacity (FVC) 1.
Key clinical context: Rituximab should be prioritized over TNF inhibitors, which are conditionally recommended against as first-line therapy for RA-ILD 2. This is critical because TNF inhibitors may worsen ILD in some patients.
Dosing Regimen
Based on FDA labeling and clinical trial data for ANCA-associated vasculitis (which provides the most relevant dosing framework for autoimmune ILD):
- Induction dosing: Two 500-1,000 mg IV infusions separated by 2 weeks (Day 1 and Day 15) 3
- Maintenance dosing: 500-1,000 mg IV every 6 months for ongoing disease control 3
- Premedication required: Antihistamine and acetaminophen before each infusion; background corticosteroids are typically used 3
The FDA labeling demonstrates this regimen achieved disease control in GPA/MPA studies, with the safety profile remaining consistent across 4 years of treatment 3.
Clinical Efficacy Data
Real-world evidence shows:
- Stabilization or improvement in 65% of RA-ILD patients treated with rituximab 4
- No significant decline in FVC or DLCO in pooled meta-analysis (FVC mean difference -0.85%, 95% CI -2.40 to 0.71; p=0.29) 5
- Comparable mortality outcomes to tocilizumab in head-to-head comparative effectiveness studies 6
- Lower mortality compared to no treatment in network meta-analysis 7
Important Caveat on Treatment Response
Rituximab does not universally prevent progression—approximately 35% of patients may still experience progressive ILD despite treatment 4. Additionally, some patients develop new-onset RA-ILD while on rituximab, suggesting it is not universally protective 4.
Safety Monitoring Protocol
Infection Risk (Primary Safety Concern)
- Incidence: 62% of patients experience infections of any type; 11% experience serious infections (rate: 25 per 100 patient-years) 3
- Most common infections: Upper respiratory tract infections, urinary tract infections, herpes zoster, and pneumonia 3
- Monitoring strategy:
- Baseline screening for hepatitis B, tuberculosis, and HIV
- Monitor for signs/symptoms of infection at each visit
- Lower threshold for empiric antibiotics in febrile patients
- Consider prophylaxis for Pneumocystis jirovecii in high-risk patients
Hypogammaglobulinemia
At 6 months post-treatment, significant proportions develop low immunoglobulin levels:
- Low IgA: 27% of patients
- Low IgG: 58% of patients
- Low IgM: 51% of patients 3
Monitoring protocol:
- Check baseline IgG, IgA, IgM levels before initiating therapy
- Recheck immunoglobulin levels every 6 months
- Consider IVIG replacement if IgG <400 mg/dL with recurrent infections
Infusion-Related Reactions
- Incidence: 12% of patients experience infusion reactions, highest with first infusion (12%), decreasing with subsequent infusions (5%, 4%, 1%) 3
- Management: Premedication with antihistamine and acetaminophen; background corticosteroids mitigate severity 3
- Symptoms: Cytokine release syndrome, flushing, throat irritation, tremor 3
Special Considerations for Patient Selection
When Rituximab May Be Preferred
Patients with elevated inflammatory markers: A 2026 comparative effectiveness study found that in patients with high baseline inflammatory markers, rituximab demonstrated better safety than tocilizumab, with lower risks of mechanical ventilation (HR 0.52) and mortality (HR 0.71) 6
Seropositive RA: Anti-CCP/RF positivity is associated with higher likelihood of initiating guideline-recommended therapies including rituximab 8
Patients requiring B-cell depletion: Rituximab's mechanism targets CD20+ B lymphocytes, which may be particularly relevant in antibody-mediated disease 9
When to Consider Alternatives
- Rapidly progressive ILD: While rituximab is conditionally recommended for rapidly progressive SARD-ILD, combination therapy (double or triple therapy) is preferred over monotherapy 2
- Contraindications to B-cell depletion: Active serious infections, severe hypogammaglobulinemia at baseline
- Prior rituximab failure: Consider mycophenolate (highest-ranked first-line agent) or abatacept 2
Real-World Treatment Patterns
Despite guideline recommendations, rituximab remains underutilized in clinical practice. A 2026 VA study of 4,108 RA-ILD patients found only 1.2-12% received ACR/CHEST guideline-recommended first-line therapies (including rituximab) after ILD diagnosis 8. This represents a significant evidence-practice gap.
Pulmonary Function Monitoring
- Baseline: FVC, DLCO, and high-resolution CT chest
- Follow-up: Repeat PFTs every 3-6 months
- Progression defined as: ≥10% decline in FVC and/or ≥15% decline in DLCO, or radiographic progression on chest CT 4
Concomitant Therapy Considerations
Methotrexate: The 2025 Italian meta-analysis found methotrexate was associated with reduced ILD progression and mortality 1. However, methotrexate use typically decreases after ILD diagnosis in real-world practice (47.1% to 30.4%) 8. The decision to continue or discontinue methotrexate should be individualized based on ILD pattern and severity.
Corticosteroids: Prednisone is commonly used (76.7% post-ILD diagnosis) 8, though short-term use (≤3 months) is preferred to minimize toxicity 2.